NO20044192L - 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater - Google Patents

17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater

Info

Publication number
NO20044192L
NO20044192L NO20044192A NO20044192A NO20044192L NO 20044192 L NO20044192 L NO 20044192L NO 20044192 A NO20044192 A NO 20044192A NO 20044192 A NO20044192 A NO 20044192A NO 20044192 L NO20044192 L NO 20044192L
Authority
NO
Norway
Prior art keywords
ostratrienes
17alpha
17beta
oxy
alkyl
Prior art date
Application number
NO20044192A
Other languages
English (en)
Inventor
Rolf Bohlmann
Orlin Petrov
Nikolaus Heinrich
Jorg Kroll
Jens Hoffmann
Rosemarie Lichtner
Rolf Jautelat
Andreas Reichel
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20044192L publication Critical patent/NO20044192L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20044192A 2001-11-27 2004-10-04 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater NO20044192L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10159217A DE10159217A1 (de) 2001-11-27 2001-11-27 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
PCT/EP2002/013484 WO2003045972A1 (de) 2001-11-27 2002-11-27 17α-ALKYL-17β-OXY-ESTRATRIENE UND ZWISCHENPRODUKTE ZU DEREN HERSTELLUNG, VERWENDUNG DER 17α-ALKYL-17β-OXY-ESTRATRIENE ZUR HERSTELLUNG VON ARZNEIMITTELN SOWIE PHARMAZEUTISCHE PRÄPARATE

Publications (1)

Publication Number Publication Date
NO20044192L true NO20044192L (no) 2004-10-04

Family

ID=7707804

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20042694A NO326241B1 (no) 2001-11-27 2004-06-25 17 alfa-alkyl-17 beta-oksy-ostratriener og mellomprodukter for fremstilling av disse, anvendelse av 17 alfa-alkyl-17 beta-oksy-ostratrienene til fremstilling av legemidler samt farmasoytiske preparater
NO20044192A NO20044192L (no) 2001-11-27 2004-10-04 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20042694A NO326241B1 (no) 2001-11-27 2004-06-25 17 alfa-alkyl-17 beta-oksy-ostratriener og mellomprodukter for fremstilling av disse, anvendelse av 17 alfa-alkyl-17 beta-oksy-ostratrienene til fremstilling av legemidler samt farmasoytiske preparater

Country Status (25)

Country Link
US (2) US7018994B2 (no)
EP (2) EP1916254A3 (no)
JP (3) JP2005513039A (no)
KR (1) KR100956912B1 (no)
CN (2) CN100558741C (no)
AR (1) AR037674A1 (no)
AT (1) ATE396198T1 (no)
AU (1) AU2002360949A1 (no)
BR (1) BR0214469A (no)
CA (1) CA2468412C (no)
CY (1) CY1108279T1 (no)
DE (2) DE10159217A1 (no)
DK (1) DK1448591T3 (no)
ES (1) ES2307819T3 (no)
IL (2) IL162200A0 (no)
MX (1) MXPA04005015A (no)
NO (2) NO326241B1 (no)
PE (1) PE20030727A1 (no)
PL (1) PL207955B1 (no)
PT (1) PT1448591E (no)
RU (2) RU2285009C2 (no)
TW (1) TWI256891B (no)
UY (1) UY27552A1 (no)
WO (1) WO2003045972A1 (no)
ZA (2) ZA200405029B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
JP2007506805A (ja) 2004-07-27 2007-03-22 シコール インコーポレイティド ７α−アルキル化された１９−ノルステロイドの調製方法
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
JP4724073B2 (ja) 2006-08-17 2011-07-13 富士通株式会社 レジストパターンの形成方法、半導体装置及びその製造方法
DE102007023614A1 (de) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007049630A1 (de) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2033948A1 (en) * 2007-08-30 2009-03-11 Bayer Schering Pharma Aktiengesellschaft Process for preparing Estrogen-antagonistic 11beta-Fluoro-17alpha-alkylestra-1,3,5 (10)-triene-3, 17-diols having a 7alpha-(xi-Alkylamino-omega-perfluoroalkyl)alkyl side chain and alpha-Alkyl(amino)-omega-perfluoro(alkyl)alkanes and processes for their preparation
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2070942A1 (de) 2007-12-13 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Aromatisierung von 19-Nor-androst-4-en-3-onen zu Estra-1,3,5(10)-trienen
EP2070941A1 (en) 2007-12-14 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Stereoselective synthesis of selective estrogen receptor down-regulators
EP2070909A1 (de) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
DE102008057230A1 (de) 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
EP2258375A1 (de) 2009-06-04 2010-12-08 Bayer Schering Pharma Aktiengesellschaft 17B-alkyl-17alpha-oxy-estratriene
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
SG186333A1 (en) 2010-06-16 2013-01-30 Endorech Inc Methods of treating or preventing estrogen-related diseases
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
PL2983671T4 (pl) 2013-04-11 2019-04-30 Bayer Pharma AG Postać dawkowania antagonisty receptora progesteronowego
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11624095B2 (en) 2017-09-27 2023-04-11 Case Western Reserve University Method of quantifying HIV reservoirs by induced transcription based sequencing
RU2750488C1 (ru) * 2020-06-03 2021-06-28 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 1,2,4-Оксадиазольные производные дезоксихолевой кислоты, обладающие простатопротекторным действием, гипохолестеринемической и противовоспалительной активностями
CN116535454A (zh) * 2023-04-28 2023-08-04 香港中文大学（深圳） 氟维司群类化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36654A (en) * 1970-04-24 1974-07-31 Ciba Geigy Ag 3-cyclopentyl ethers of 7alpha-methyl-3,16alpha,17(alpha and beta)-trihydroxy-delta 1,3,5(10)-estratriene,their manufacture and estrogenic pharmaceutical compositions containing them
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
EP0310542B1 (de) 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
DE19510862A1 (de) 1995-03-16 1996-09-19 Schering Ag Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle
DE19622457A1 (de) * 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
PL334920A1 (en) 1997-01-30 2000-03-27 Dsm Nv Composition crossclinkable by irradiation
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
AR015500A1 (es) * 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
DE19807791A1 (de) 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen
DE10019171A1 (de) 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
CA2423017C (en) 2000-10-18 2009-01-06 Bayer Schering Pharma Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
PT1448591E (pt) 2008-09-19
CN1637015A (zh) 2005-07-13
CN1325507C (zh) 2007-07-11
DE10159217A1 (de) 2003-06-05
HK1077832A1 (en) 2006-02-24
TW200305426A (en) 2003-11-01
RU2285009C2 (ru) 2006-10-10
CA2468412A1 (en) 2003-06-05
ZA200405029B (en) 2009-07-29
RU2004119437A (ru) 2005-07-10
AR037674A1 (es) 2004-12-01
WO2003045972A1 (de) 2003-06-05
NO20042694L (no) 2004-07-22
IL162200A (en) 2010-06-30
ES2307819T3 (es) 2008-12-01
JP2005513039A (ja) 2005-05-12
ZA200407868B (en) 2005-04-26
DK1448591T3 (da) 2008-09-29
BR0214469A (pt) 2004-10-13
CN1617879A (zh) 2005-05-18
NO326241B1 (no) 2008-10-27
HK1079215A1 (en) 2006-03-31
JP2005120110A (ja) 2005-05-12
KR100956912B1 (ko) 2010-05-11
US20060009436A1 (en) 2006-01-12
AU2002360949A1 (en) 2003-06-10
PE20030727A1 (es) 2003-09-18
UY27552A1 (es) 2003-06-30
US7018994B2 (en) 2006-03-28
JP2006306896A (ja) 2006-11-09
EP1448591B1 (de) 2008-05-21
CA2468412C (en) 2010-01-12
EP1916254A3 (de) 2012-11-14
US20030191099A1 (en) 2003-10-09
DE50212302D1 (de) 2008-07-03
EP1916254A2 (de) 2008-04-30
CY1108279T1 (el) 2014-02-12
JP4335820B2 (ja) 2009-09-30
PL207955B1 (pl) 2011-02-28
PL369171A1 (en) 2005-04-18
IL162200A0 (en) 2005-11-20
EP1448591A1 (de) 2004-08-25
US7538100B2 (en) 2009-05-26
RU2006120215A (ru) 2008-01-10
RU2339643C2 (ru) 2008-11-27
ATE396198T1 (de) 2008-06-15
MXPA04005015A (es) 2005-04-08
KR20040063158A (ko) 2004-07-12
CN100558741C (zh) 2009-11-11
TWI256891B (en) 2006-06-21

Similar Documents

Publication Publication Date Title
NO20033556D0 (no) Farmasöytiske preparater
NO20071303L (no) Farmasoytiske preparater
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
KR20050009999A (ko) 약제학적 제제
NO20021401D0 (no) Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
EP1412378A4 (en) APTAMERS AND ANTIAPTAMERS
DK1370128T3 (da) Kombineret ballepresse og ballevikler
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
NO20020304L (no) Konserverte farmasoytiske preparater
IS8153A (is) Ónæmisbælandi efnasambönd og efnablöndur
IS2504B (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
NO20041975L (no) Bicyklisk oksopyridin og oksopyrimidinderivater
EE200300416A (et) Ravimvorm
NO20025357L (no) Antranylamider og deres anvendelse som legemidler
NO20035315D0 (no) Farmasöytiske kombinasjoner
IS2841B (is) Samstæða hluta og lyfjasamsetningar
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
DK1407780T3 (da) Farmaceutisk stabile hæmostatiske præparater
NO20042693L (no) Kateterpreparat og anvendelser derav
NO20023144D0 (no) Kompleks omfattende OCIF og polysakkarid
NO20030156L (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
DK1849468T3 (da) Farmaceutisk sammensætning omfattende roflumilast og levocetirizin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application